Comparative effectiveness of BNT162B2 and mRNA-1273 vaccines in U.S. Veterans

Comparative effectiveness of BNT162B2 and mRNA-1273 vaccines in U.S. Veterans

The messenger RNA (mRNA)–based vaccines BNT162b2 and mRNA-1273 are more than 90% effective against coronavirus disease 2019 (Covid-19). However, their comparative effectiveness for a range of outcomes across diverse populations is unknown. METHODS We emulated a target trial using the electronic heal...

Full description

Bibliographic Details
Main Authors: Casas, J.P (Author), Cho, K. (Author), Dickerman, B.A (Author), Ferolito, B.R (Author), Figueroa, M.J (Author), Gagnon, D.R (Author), Gaziano, J.M (Author), Gerlovin, H. (Author), Hernán, M.A (Author), Kurgansky, K.E (Author), Madenci, A.L (Author)
Format: Article
Language:English
Published: Massachussetts Medical Society 2022
Subjects:
2019-nCoV Vaccine mRNA-1273
adult
Adult
aged
Aged
Aged, 80 and over
BNT162 Vaccine
comparative study
COVID-19
epidemiology
female
Female
hospitalization
Hospitalization
human
Humans
incidence
Incidence
intensive care unit
Intensive Care Units
male
Male
middle aged
Middle Aged
mortality
prevention and control
risk factor
Risk Factors
United States
vaccine
Vaccine Efficacy
very elderly
veteran
Veterans
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items